Search
brexucabtagene autoleucel (Tecartus, Zynteglo)
Indications:
- treatment of adults with relapsed/refractory mantle cell lymphoma
- relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)
Dosage:
- suspension of CAR-positive viable T-cells for infusion
* 20,000,000 CELLS/ML Injection
Adverse effects:
- fever, cytokine release syndrome, hypotension, encephalopathy, fatigue, tachycardia, arrhythmia, infections, chills,hypoxia, cough, tremor, musculoskeletal pain, headache, nausea/vomiting, edema, motor dysfunction, constipation, diarrhea, anorexia, dyspnea, rash, insomnia, pleural effusion, aphasia
* Warnings
- hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome
- hypersensitivity
- prolonged cytopenias
- hypogammaglobulinemia
- secondary malignancies
- Effects on Ability to Drive and Use Machines
Mechanism of action:
- CD19-directed genetically modified autologous car T-cell immunotherapy
General
chimeric antigen-receptor (CAR) T-cell therapy; tisagenlecleucel; CTL019 (Kymriah)
References
- FDA Cellular and Gene Therapy Products. Aug 14, 2020
TECARTUS (brexucabtagene autoleucel)
https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/tecartus-brexucabtagene-autoleucel
- FDA July 27, 2020
FDA approves brexucabtagene autoleucel for relapsed or refractory
mantle cell lymphoma
https://www.fda.gov/drugs/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-mantle-cell-lymphoma
- WikipediaL Brexucabtagene autoleucel
https://en.wikipedia.org/wiki/Brexucabtagene_autoleucel